RedHill Biopharma (RDHL) Posts Smaller Q1 Loss

RedHill Biopharma (NASDAQ: RDHL) reported Q1 EPS of ($0.03), $0.20 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $18.2 million versus the consensus estimate of $24.3 million.

For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.

You May Also Be Interested In

• Cerebras CEO says investors misunderstood margin guidance
• Jefferies Financial Group (JEF) Misses Q2 EPS by 22c
• Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c